Jun-Ichiro Koga1, Toshiaki Nakano1, James E Dahlman2,3,4, Jose-Luiz Figueiredo1,5, Hengmin Zhang5, Julius Decano5, Omar F Khan2,3,4, Tomiharu Niida1, Hiroshi Iwata5, Jon C Aster6, Hideo Yagita7, Daniel G Anderson2,3,4,8, C Keith Ozaki9, Masanori Aikawa1,5,10. 1. The Center for Excellence in Vascular Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. 2. David H. Koch Institute for Integrative Cancer Research, Cambridge, MA. 3. Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA. 4. Institutes for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA. 5. the Center for Interdisciplinary Cardiovascular Sciences, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. 6. Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. 7. Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan. 8. Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA. 9. Division of Vascular and Endovascular Surgery, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. 10. Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Abstract
OBJECTIVE: Despite its large clinical impact, the underlying mechanisms for vein graft failure remain obscure and no effective therapeutic solutions are available. We tested the hypothesis that Notch signaling promotes vein graft disease. APPROACH AND RESULTS: We used 2 biotherapeutics for Delta-like ligand 4 (Dll4), a Notch ligand: (1) blocking antibody and (2) macrophage- or endothelial cell (EC)-targeted small-interfering RNA. Dll4 antibody administration for 28 days inhibited vein graft lesion development in low-density lipoprotein (LDL) receptor-deficient (Ldlr(-/-)) mice, and suppressed macrophage accumulation and macrophage expression of proinflammatory M1 genes. Dll4 antibody treatment for 7 days after grafting also reduced macrophage burden at day 28. Dll4 silencing via macrophage-targeted lipid nanoparticles reduced lesion development and macrophage accumulation, whereas EC-targeted Dll4 small-interfering RNA produced no effects. Gain-of-function and loss-of-function studies suggested in vitro that Dll4 induces proinflammatory molecules in macrophages. Macrophage Dll4 also stimulated smooth muscle cell proliferation and migration and suppressed their differentiation. CONCLUSIONS: These results suggest that macrophage Dll4 promotes lesion development in vein grafts via macrophage activation and crosstalk between macrophages and smooth muscle cells, supporting the Dll4-Notch axis as a novel therapeutic target.
OBJECTIVE: Despite its large clinical impact, the underlying mechanisms for vein graft failure remain obscure and no effective therapeutic solutions are available. We tested the hypothesis that Notch signaling promotes vein graft disease. APPROACH AND RESULTS: We used 2 biotherapeutics for Delta-like ligand 4 (Dll4), a Notch ligand: (1) blocking antibody and (2) macrophage- or endothelial cell (EC)-targeted small-interfering RNA. Dll4 antibody administration for 28 days inhibited vein graft lesion development in low-density lipoprotein (LDL) receptor-deficient (Ldlr(-/-)) mice, and suppressed macrophage accumulation and macrophage expression of proinflammatory M1 genes. Dll4 antibody treatment for 7 days after grafting also reduced macrophage burden at day 28. Dll4 silencing via macrophage-targeted lipid nanoparticles reduced lesion development and macrophage accumulation, whereas EC-targeted Dll4 small-interfering RNA produced no effects. Gain-of-function and loss-of-function studies suggested in vitro that Dll4 induces proinflammatory molecules in macrophages. Macrophage Dll4 also stimulated smooth muscle cell proliferation and migration and suppressed their differentiation. CONCLUSIONS: These results suggest that macrophage Dll4 promotes lesion development in vein grafts via macrophage activation and crosstalk between macrophages and smooth muscle cells, supporting the Dll4-Notch axis as a novel therapeutic target.
Authors: Mark W Majesky; Xiu Rong Dong; Virginia Hoglund; William M Mahoney; Guenter Daum Journal: Arterioscler Thromb Vasc Biol Date: 2011-07 Impact factor: 8.311
Authors: Gabriel Courties; Timo Heidt; Matthew Sebas; Yoshiko Iwamoto; Derrick Jeon; Jessica Truelove; Benoit Tricot; Greg Wojtkiewicz; Partha Dutta; Hendrik B Sager; Anna Borodovsky; Tatiana Novobrantseva; Boris Klebanov; Kevin Fitzgerald; Daniel G Anderson; Peter Libby; Filip K Swirski; Ralph Weissleder; Matthias Nahrendorf Journal: J Am Coll Cardiol Date: 2013-12-18 Impact factor: 24.094
Authors: Teresa Coelho; David Adams; Ana Silva; Pierre Lozeron; Philip N Hawkins; Timothy Mant; Javier Perez; Joseph Chiesa; Steve Warrington; Elizabeth Tranter; Malathy Munisamy; Rick Falzone; Jamie Harrop; Jeffrey Cehelsky; Brian R Bettencourt; Mary Geissler; James S Butler; Alfica Sehgal; Rachel E Meyers; Qingmin Chen; Todd Borland; Renta M Hutabarat; Valerie A Clausen; Rene Alvarez; Kevin Fitzgerald; Christina Gamba-Vitalo; Saraswathy V Nochur; Akshay K Vaishnaw; Dinah W Y Sah; Jared A Gollob; Ole B Suhr Journal: N Engl J Med Date: 2013-08-29 Impact factor: 91.245
Authors: Erik Fung; Sai-Man Timothy Tang; James P Canner; Kunio Morishige; Joseph F Arboleda-Velasquez; Angelo A Cardoso; Nadia Carlesso; Jon C Aster; Masanori Aikawa Journal: Circulation Date: 2007-05-28 Impact factor: 29.690
Authors: Richard D Kenagy; Nozomi Fukai; Seung-Kee Min; Florencia Jalikis; Ted R Kohler; Alexander W Clowes Journal: J Vasc Surg Date: 2009-05 Impact factor: 4.268
Authors: Florian Leuschner; Partha Dutta; Rostic Gorbatov; Tatiana I Novobrantseva; Jessica S Donahoe; Gabriel Courties; Kang Mi Lee; James I Kim; James F Markmann; Brett Marinelli; Peter Panizzi; Won Woo Lee; Yoshiko Iwamoto; Stuart Milstein; Hila Epstein-Barash; William Cantley; Jamie Wong; Virna Cortez-Retamozo; Andita Newton; Kevin Love; Peter Libby; Mikael J Pittet; Filip K Swirski; Victor Koteliansky; Robert Langer; Ralph Weissleder; Daniel G Anderson; Matthias Nahrendorf Journal: Nat Biotechnol Date: 2011-10-09 Impact factor: 54.908
Authors: Cory D Sago; Melissa P Lokugamage; Fatima Z Islam; Brandon R Krupczak; Manaka Sato; James E Dahlman Journal: J Am Chem Soc Date: 2018-11-16 Impact factor: 15.419
Authors: Toshiaki Nakano; Shunsuke Katsuki; Mingxian Chen; Julius L Decano; Arda Halu; Lang Ho Lee; Diego V S Pestana; Angelo S T Kum; Rodrigo K Kuromoto; Whitney S Golden; Mario S Boff; Gabriel C Guimaraes; Hideyuki Higashi; Kevin J Kauffman; Takashi Maejima; Takehiro Suzuki; Hiroshi Iwata; Albert-László Barabási; Jon C Aster; Daniel G Anderson; Amitabh Sharma; Sasha A Singh; Elena Aikawa; Masanori Aikawa Journal: Circulation Date: 2019-01-02 Impact factor: 29.690
Authors: Ryo Kawakami; Shunsuke Katsuki; Richard Travers; Dayanna Carolina Romero; Dakota Becker-Greene; Livia Silva Araujo Passos; Hideyuki Higashi; Mark C Blaser; Galina K Sukhova; Josef Buttigieg; David Kopriva; Ann Marie Schmidt; Daniel G Anderson; Sasha A Singh; Luis Cardoso; Sheldon Weinbaum; Peter Libby; Masanori Aikawa; Kevin Croce; Elena Aikawa Journal: Arterioscler Thromb Vasc Biol Date: 2020-05-28 Impact factor: 8.311
Authors: Margreet R de Vries; Karin H Simons; J Wouter Jukema; Jerry Braun; Paul H A Quax Journal: Nat Rev Cardiol Date: 2016-05-19 Impact factor: 32.419